This article is more than 5 years old. Information may no longer be current.
Greater improvements in HbA1c, body weight with canagliflozin vs. sitagliptin
Click Here to Manage Email Alerts
Results from a 52-week, randomized, double blind, phase 3 study of canagliflozin demonstrate improved glycemic control and body weight reduction vs. sitagliptin in patients with type 2 diabetes. However, canagliflozin was associated with increased genital infections.
The study included patients taking metformin plus sulfonylurea (n=755) randomly assigned to canagliflozin 300 mg (Invokana, Janssen Pharmaceuticals) or sitagliptin 100 mg (Januvia, Merck) daily.
Patients assigned canagliflozin demonstrated no inferiority at 52 weeks. Upon further analysis, patients in the canagliflozin group (21.03%) showed significantly greater reductions in HbA1c compared with those assigned to sitagliptin 100 mg (20.66%). The least squares mean difference between groups was –0.37% (95% CI, −0.50 to −0.25), according to data.
The researchers also observed greater reductions in fasting plasma glucose, body weight and systolic BP with canagliflozin vs. sitagliptin (P<.001), they wrote.
Moreover, the overall adverse event rates were similar with canagliflozin (76.7%) and sitagliptin (77.5%), whereas the incidence for serious adverse events and adverse event-related discontinuations were low in both groups, they wrote.
As with most sodium-glucose cotransporter 2 inhibitors, the researchers reported higher incidences of genital mycotic infections and osmotic diuresis-related adverse events in patients assigned to canagliflozin.
Disclosure: See the study for a full list of disclosures.
Click Here to Manage Email Alerts